Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: Influence of food intake

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 31, Issue 2, 2012, Pages 161-167

  Eiden, C ^a,d   Meniane, J C ^a   Peyriere H ^a,b,c   Eymard Duvernay, S ^b   Le Falher, G ^a   Ceballos, P ^a   Fegueux, N ^a   Cociglio, M ^a   Reynes, J ^a,b   Hillaire Buys, D ^a  

^a MONTPELLIER UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE MONTPELLIER   (France)

^c UNIV MONTPELLIER   (France)

^d LAPEYRONIE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

POSACONAZOLE; PROTON PUMP INHIBITOR;

ADOLESCENT; ADULT; AGE; AGED; ANTIFUNGAL PROPHYLAXIS; ARTICLE; BODY WEIGHT; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOOD; FOOD DRUG INTERACTION; FOOD INTAKE; GENDER; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MUCOSA INFLAMMATION; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; SIDE EFFECT; SYSTEMIC MYCOSIS; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; CHEMOPREVENTION; DRUG MONITORING; EATING; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MYCOSES; TRIAZOLES; YOUNG ADULT;

EID: 84857058536     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-011-1288-9     Document Type: Article

References (19)

1. OA Cornely J Maertens DJ Winston, et al. 2007 Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia N Engl J Med 356 348 359 17251531 10.1056/NEJMoa061094 1:CAS:528:DC%2BD2sXhtVGrsrw%3D (Pubitemid 46148777)
2. AJ Ullmann JH Lipton DH Vesole, et al. 2007 Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease N Engl J Med 356 335 347 17251530 10.1056/NEJMoa061098 1:CAS:528:DC%2BD2sXhtVGktb4%3D (Pubitemid 46148776)
3. R Courtney S Pai M Laughlin, et al. 2003 Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults Antimicrob Agents Chemother 47 2788 2795 12936975 10.1128/AAC.47.9.2788-2795.2003 1:CAS:528:DC%2BD3sXntFegs7c%3D (Pubitemid 37040249)
4. R Courtney D Wexler E Radwanski, et al. 2004 Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults Br J Clin Pharmacol 57 218 222 14748822 10.1046/j.1365-2125.2003.01977.x (Pubitemid 38223535)
5. G Krishna A Sansone-Parsons M Martinho, et al. 2007 Posaconazole plasma concentrations in juvenile patients with invasive fungal infection Antimicrob Agents Chemother 51 812 818 17210771 10.1128/AAC.00454-06 1:CAS:528: DC%2BD2sXis1yqu70%3D (Pubitemid 46355260)
6. PO Gubbins G Krishna A Sansone-Parsons, et al. 2006 Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients Antimicrob Agents Chemother 50 1993 1999 16723557 10.1128/AAC.00157-06 1:CAS:528:DC%2BD28XlsVOitLk%3D (Pubitemid 43807517)
7. G Krishna M Martinho P Chandrasekar, et al. 2007 Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease Pharmacotherapy 27 1627 1636 18041883 10.1592/phco.27.12.1627 1:CAS:528:DC%2BD2sXhsVygtr%2FM (Pubitemid 350234311)
8. G Krishna M AbuTarif F Xuan, et al. 2008 Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome Pharmacotherapy 28 1223 1232 18823218 10.1592/phco.28.10.1223 1:CAS:528:DC%2BD1cXht1OntbzE
9. F Ezzet D Wexler R Courtney, et al. 2005 Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations Clin Pharmacokinet 44 211 220 15656699 10.2165/00003088-200544020-00006 1:CAS:528:DC%2BD2MXhvVCltrs%3D (Pubitemid 40188942)
10. G Krishna A Moton L Ma, et al. 2009 Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers Antimicrob Agents Chemother 53 958 966 19075045 10.1128/AAC.01034-08 1:CAS:528:DC%2BD1MXivF2lur4%3D
11. SH Jang PM Colangelo JV Gobburu 2010 Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma Clin Pharmacol Ther 88 115 119 20505665 10.1038/clpt.2010.64 1:CAS:528:DC%2BC3cXns1Gjsr0%3D
12. TJ Walsh I Raad TF Patterson, et al. 2007 Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial Clin Infect Dis 44 2 12 17143808 10.1086/508774 1:CAS:528:DC%2BD2sXnvVCjtg%3D%3D (Pubitemid 44968977)
13. D Lebeaux F Lanternier C Elie, et al. 2009 Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults Antimicrob Agents Chemother 53 5224 5229 19752284 10.1128/AAC.00939-09 1:CAS:528:DC%2BD1MXhsF2gs7fO
14. AM Bryant D Slain A Cumpston, et al. 2011 A post-marketing evaluation of posaconazole plasma concentrations in neutropenic patients with haematological malignancy receiving posaconazole prophylaxis Int J Antimicrob Agents 37 266 269 21236645 10.1016/j.ijantimicag.2010.11.021 1:CAS:528:DC%2BC3MXit12hs7g%3D
15. B De Pauw TJ Walsh JP Donnelly European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group, et al. 2008 Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group Clin Infect Dis 46 1813 1821 18462102 10.1086/588660
16. D Andes A Pascual O Marchetti 2009 Antifungal therapeutic drug monitoring: established and emerging indications Antimicrob Agents Chemother 53 24 34 18955533 10.1128/AAC.00705-08 1:CAS:528:DC%2BD1MXhs1Klu7c%3D
17. EJ Rachwalski JT Wieczorkiewicz MH Scheetz 2008 Posaconazole: an oral triazole with an extended spectrum of activity Ann Pharmacother 42 1429 1438 18713852 10.1345/aph.1L005 1:CAS:528:DC%2BD1cXht1enur3J
18. GR Thompson 3rd MG Rinaldi G Pennick, et al. 2009 Posaconazole therapeutic drug monitoring: a reference laboratory experience Antimicrob Agents Chemother 53 2223 2224 19258264 10.1128/AAC.00240-09 1:CAS:528: DC%2BD1MXlvVGnsLs%3D
19. A Moton G Krishna Z Wang 2009 Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers J Clin Pharm Ther 34 301 311 19646076 10.1111/j.1365-2710.2009.01055.x 1:CAS:528:DC%2BD1MXmvVCjsL8%3D